Cellular Senescence and Senolytics: What Human Trials Have Measured

Clinical journalGlossary

Cellular Senescence and Senolytics: What Human Trials Have Measured

1 minute read

Evidence-informed reading from the Regeneration Center.

Page last updated

What happens to a senescent cell?

A senescent cell stays alive but stops dividing for a prolonged period. It can still release signals that affect nearby tissue. This differs from apoptosis, in which the cell dies. Senolytics are being studied for their ability to remove certain senescent cells. In a mouse model of accelerated aging, removing cells marked by p16 delayed some age-related changes. That result applies to the model and does not establish a treatment for human aging. [1, 2]

What did the randomized human studies find?

In a phase 2 trial of 60 postmenopausal women, dasatinib plus quercetin did not improve the primary measure of bone resorption at 20 weeks versus control. A secondary bone formation marker changed at weeks two and four, but the difference was absent at week 20. That finding does not establish fracture prevention. [3]

A separate 12-person pilot in idiopathic pulmonary fibrosis primarily assessed feasibility and tolerability. It did not find meaningful between-group differences in the exploratory measures of physical or lung function over its short follow-up. These studies do not establish a senolytic regimen for the general public. [4]

Sources

  1. Nomenclature Committee on Cell Death consensus
  2. Baker et al., original mouse study of p16-positive cell clearance
  3. Farr et al., randomized bone metabolism trial
  4. Nambiar et al., randomized pulmonary fibrosis pilot
Continue exploring

Three related medical articles and reference pages.